



**Summarised Group** results  
for the 12 months ended  
**30 September 2024**  
and cash distributions



# HIGHLIGHTS



Leading provider of value-based care

Patient-centred care through innovative contracting and reimbursement models



Diversified offering

With an expansion into integral diagnostic and adjacent lines of business



People centred and patient insight driven

Positively impacting patient care through a focus on our employees, clinicians, and the utilisation of data analysis and technology

## Southern Africa (SA)

Acute PPD<sup>1</sup> growth

↑ 1.6%

Strong revenue growth and margin improvement<sup>2</sup> in H2-2024

Revenue growth

↑ 7.7%

Concluded FMC<sup>3</sup> SA renal business acquisition

## Life Molecular Imaging (LMI)

NeuraCeq® doses sold

↑ 91.9%

RM2 sub-licensing transaction

Revenue growth

↑ 181.3%

Normalised EBITDA

↑ >100%

<sup>1</sup> Paid patient days

<sup>2</sup> In acute and complementary

<sup>3</sup> Fresenius Medical Care renal business

*Making life better*

# HIGHLIGHTS



Leading provider of value-based care

Patient-centred care through innovative contracting and reimbursement models



Diversified offering

With an expansion into integral diagnostic and adjacent lines of business



People centred and patient insight driven



Positively impacting patient care through a focus on our employees, clinicians, and the utilisation of data analysis and technology

Group	Revenue growth	NEPS	Final dividend 31.0 cps ↑ 14.8 % Special dividend 70.0 cps	Total dividend FY2024  720 cps R10.6bn
	↑ 12.7%	↑ 48.5%		


*Making life better*

**Life** Healthcare

# STRATEGY








Making life better

## International

- Life Molecular Imaging (LMI)

## Southern Africa

- Employer based on-site occupational health and wellness
- 2 cyclotrons
- 3 PET-CT sites
- 7 imaging sites
- 1 012 renal dialysis stations
- 5 oncology units



## Southern Africa

- 71 healthcare facilities
- Acute hospitals:
  - 48 facilities
  - 8 308 beds
- Mental health facilities:
  - 9 facilities
  - 607 beds
- Acute rehabilitation units:
  - 7 units
  - 287 rehabilitation beds
- 2 341 PPP<sup>1</sup> beds


<sup>1</sup> Public-private partnerships – Life Nkanyisa

## International

- Life Molecular Imaging (LMI)

## Southern Africa

- Employer based on-site occupational health and wellness
- 2 cyclotrons
- 3 PET-CT sites
- 7 imaging sites
- 1 012 renal dialysis stations
- 5 oncology units






## Southern Africa

- 71 healthcare facilities
- Acute hospitals:
  - 48 facilities
  - 8 308 beds
- Mental health facilities:
  - 9 facilities
  - 607 beds
- Acute rehabilitation units:
  - 7 units
  - 287 rehabilitation beds
- 2 341 PPP<sup>1</sup> beds

<sup>1</sup> Public-private partnerships – Life Nkanyisa





# SA OPERATIONAL REVIEW






# YTD 2024 | SOUTHERN AFRICA



Overall occupancy<sup>1</sup> %




- Continued improvement in overall occupancy
- Good improvement in acute occupancy
- Top 20 facilities occupancy of 71%

<sup>1</sup> Excludes PPDs of two facilities closed in H1-2023

# YTD 2024 ACUTE HOSPITALS | STRONG H2-2024

Occupancy<sup>1</sup> %



	vs 2023		
	H1-2024	H2-2024	FY2024
PPDs	2.7%	0.7%	1.6%
Revenue / PPD	2.8%	6.5%	4.7%
Revenue	5.5%	7.5%	6.5%
Normalised EBITDA <sup>2</sup>	15.0% / 16.6%	15.9% / 15.8%	15.4% / 16.2%

- Occupancy % 68.7% → Continued improvement in occupancy %
- PPD growth<sup>1</sup> 1.6% → Good underlying growth but slower in H2-2024 due to higher overall occupancies
- Revenue / PPD 4.7% → Above CPI tariff increase in January and strong revenue / PPD in H2-2024 (6.5%)
- Revenue 6.5% → Improved revenue growth of 7.5% in H2-2024
- H2-2024 margin 15.9% → Improved margin vs H1-2024 and prior year (PY)


<sup>1</sup> On a like-for-like basis

<sup>2</sup> After incentives


*Making life better*

# YTD 2024 COMPLEMENTARY SERVICES | STRONG H2-2024


MH & AR Occupancy<sup>1</sup> %



RD<sup>2</sup> treatments



Imaging volumes



- Revenue 26.9% → Acquisition of FMC renal – additional R308m in revenue
- Occupancy % 71.7% → Good occupancy level and strong mental health H2-2024 occupancy of 74.8%
- PPD growth<sup>1</sup> (2.6%) → Impacted by reduction in RAF<sup>3</sup> cases in acute rehabilitation
- Renal dialysis treatments 8.3% → Excl. FMC – benefitting from improved integrated care programme compliance
- MRI/CT/PET-CT/SPECT 17.0% → Hilton radiology (1 March 2024) and TheraMed Nuclear transaction (1 June 2023)





<sup>1</sup> MH – mental health  
AR – acute rehabilitation  
On a like-for-like basis

<sup>2</sup> Renal dialysis

<sup>3</sup> Road Accident Fund



# LIFE MOLECULAR IMAGING (LMI) REVIEW



1

DELIVER



**NeuraCeq®** demand is expected to **increase significantly**, driven by growing patient demand in the diagnosis of Alzheimer's Disease, so that they can access **disease-modifying drugs**

**c. \$2.5 billion**

Potential addressable market

2

MAXIMISE PRODUCT PIPELINE

Promising pipeline of **5 potential new products** targeting different diseases, diversifying the portfolio. **Demand for PI-2620 and CardioCeq** is expected to quickly grow when brought-to-market in 2027

3

SUSTAIN R&D\* SERVICES & SUPPLIES

Offering **R&D as a service** to clinical research organisations drives a **consistent and stable revenue stream**

THE SUCCESS OF THESE THREE PATHWAYS IS UNDERPINNED BY...


LMI's expert R&D capabilities, renowned talent and market position

\* R&D – research and development


*Making life better*



LMI revenue USD'm



NeuraCeq® volumes






- The LMI revenue includes \$36 million from a sub-licensing transaction
- Commercial sales of NeuraCeq®: doubled per half since H2-2023

*Making life better*



# FINANCIAL REVIEW



<b>Strong activity drivers result in strong revenue growth</b>	Group revenue ↑ 12.7%	SA revenue ↑ 7.7%	LMI revenue ↑ 181.3%
<b>Operational performance bolstered by the RM2 sub-licensing transaction</b>	Group normalised EBITDA ↑ 19.9%	Group operating profit ↑ 18.9%	RM2 contribution to normalised EBITDA <b>R580m</b>
<b>Earnings growth</b>	NEPS ↑ 48.5%	Net interest expense ↓ 66.5%	RM2 contribution to earnings <b>R434m</b>
<b>Fortress balance sheet</b>	AMG disposal concluded	Net debt to normalised EBITDA <b>0.45x</b>	ROCE <sup>1</sup> at ↑ <b>20.0%</b>

<sup>1</sup> Return on capital employed

*Making life better*

# FY 2024| STATEMENT OF PROFIT OR LOSS FROM CONTINUING OPERATIONS

	2024 R'm	2023 R'm	Notes	% change
Revenue	25 519	22 641	1	12.7
Normalised EBITDA	4 310	3 594	2	19.9
Normalised EBITDA margin	16.9%	15.9%		
EBITA	3 214	2 626		22.4
Amortisation	(178)	(158)		(12.7)
Non-trading net expense	(137)	(29)	3	
<b>Operating profit</b>	<b>2 899</b>	<b>2 439</b>		<b>18.9</b>
Net finance costs	(180)	(537)	4	66.5
Finance income	346	159		
Finance costs	(526)	(696)		
Associates and joint ventures	8	9		
<b>Profit before tax</b>	<b>2 727</b>	<b>1 911</b>		<b>42.7</b>
Tax	(538)	(483)	5	(11.4)
Non-controlling interest	(120)	(174)		
<b>Attributable profit</b>	<b>2 069</b>	<b>1 254</b>		<b>65.0</b>

1. Revenue growth boosted by PPD growth of 1.6<sup>1</sup> % in acute, improved revenue / PPD in H2-2024, NeuraCeq® doses sold (up 91.9%) and the RM2 transaction
2. RM2 transaction and increased incentives impacted normalised EBITDA (net positive impact R354 million)
3. Mainly includes fair value adjustments to contingent consideration (R63 million), impairments (R25 million) and retrenchment costs (R27 million)
4. Benefit of de-gearred balance sheet
5. Lower effective tax rate (19.70%) due to deferred tax raised on losses

AMG accounted for as a discontinued operations in current and PY (excluded from this slide)

<sup>1</sup> On a like-for-like basis

*Making life better*

# YTD 2024| SOUTHERN AFRICA

	2024 R'm	2023 R'm	%	H1-2024 R'm	H1-2023 R'm	%	H2-2024 R'm	H2-2023 R'm	%
<b>Revenue</b>									
<b>Southern Africa</b>									
Hospitals	20 299	19 053	6.5	9 698	9 190	5.5	10 601	9 863	7.5
Complementary services	2 045	1 612	26.9	834	773	7.9	1 211	839	44.3
Healthcare services	1 330	1 320	0.8	696	635	9.6	634	685	(7.4)
	23 674	21 985	7.7	11 228	10 598	5.9	12 446	11 387	9.3
<b>Normalised EBITDA</b>									
<b>Southern Africa</b>									
Hospitals	3 132	3 087	1.5	1 451	1 528	(5.0)	1 681	1 559	7.8
Complementary services	448	388	15.5	176	186	(5.4)	272	202	34.7
Healthcare services	104	162	(35.8)	94	83	13.3	10	79	(87.3)
<b>Corporate</b>	(11)	70	>(100)	37	45	(17.8)	(48)	25	>(100)
	3 673	3 707	(0.9)	1 758	1 842	(4.6)	1 915	1 865	2.7
<b>Normalised EBITDA margin</b>									
<b>Southern Africa</b>									
Hospitals	15.4%	16.2%		15.0%	16.6%		15.9%	15.8%	
Complementary services	21.9%	24.1%		21.1%	24.1%		22.5%	24.1%	
Healthcare services	7.8%	12.3%		13.5%	13.1%		1.6%	11.5%	
<b>Total SA incl corporate</b>	15.5%	16.9%		15.7%	17.4%		15.4%	16.4%	
<b>Corporate</b>									
Costs	(1 714)	(1 531)	(12.0)						
Recoveries	1 703	1 601	6.4						
	(11)	45							

- Revenue growth:
  - Strong H2-2024 acute and complementary growth of 10.4%
  - Revenue from complementary services for the first time above R2 billion – driven by renal dialysis and imaging
  - Life Nkanyisa: closure of Witpoort / Randfontein recovery centres, loss of Shiluvana contract, additional debtors provision
- EBITDA margins:
  - Improved margins in H2-2024 in acute and complementary
  - 10.9% increase in H2-2024 normalised EBITDA in acute and complementary
  - Impacted by Q1-2024, healthcare services and increased incentives

*Making life better*



# FY 2024 | EARNINGS PER SHARE

	2024	2023	% change
Weighted average number of shares (million)	1 443	1 442	0.1
<b>EPS from continuing operations (cents)</b>	<b>137.8</b>	87.0	58.4
<b>HEPS from continuing operations (cents)</b>	<b>139.0</b>	87.5	58.9
Adjustments to contingent consideration	9.8	4.8	
Interest saving	(11.8)	-	
Deferred taxes	(10.6)	(4.7)	
Other	5.9	1.5	
<b>NEPS (cents)</b>	<b>132.3</b>	89.1	48.5
<b>NEPS excluding sub-license transaction (cents)</b>	<b>102.2</b>	89.1	14.7

- The total net gain recognised on disposal of AMG in FY2023 and FY2024 is R1.8 billion
- EPS / HEPS from continuing operations impacted by:
  - Interest received on positive cash balance (mainly due to proceeds on sale of AMG) from 1 February 2024
  - LMI's RM2 transaction contributing R434 million to earnings

*Making life better*

# FY 2024 | FINANCIAL POSITION

	2024 R'm	2023 R'm
<b>Non-current assets</b>	<b>16 809</b>	16 201
Property, plant and equipment	10 765	10 572
Goodwill & Intangibles	3 570	3 287
Other	2 474	2 342
<b>Current assets (excluding cash)</b>	<b>4 830</b>	4 125
Cash	2 462	846
<b>Assets held for sale</b>	<b>228</b>	19 380
<b>Total assets</b>	<b>24 329</b>	40 552
<b>Total shareholders' equity</b>	<b>13 514</b>	21 289
<b>Non-current liabilities</b>	<b>5 560</b>	13 128
Interest-bearing borrowings	3 394	11 010
Other non-current liabilities	2 166	2 118
<b>Current liabilities (excluding int-bearing borrowings)</b>	<b>4 228</b>	4 142
Interest-bearing borrowings	1 027	1 992
<b>Total equity and liabilities</b>	<b>24 329</b>	40 552
Net debt	1 959	12 343
<b>Net debt to normalised EBITDA (covenant 3.5x)</b>	<b>0.45x</b>	2.00x
<b>Return on capital employed*</b>	<b>20.0%</b>	17.6%

- Strong balance sheet
- Capex spend in 2024 of R1.6 billion
- Acquisitions of R421 million
- Capex commitments FY2025 of R2.6 billion

\* Calculated as operating profit/capital employed. Capital employed = PPE plus intangibles plus current assets (exc. cash) less current liabilities (excl. overdrafts and interest-bearing borrowings)

Summarised Group results for the year ended **30 September 2024** and cash dividends declaration

*Making life better*

- The Group refinanced some of its South African debt thereby extending debt maturities and lowering margins on interest relative to reference rates
- The Group is in process of acquiring a property – included in short term portion of lease liabilities
- Debt maturity:

R'm	Balance at 30 Sep 2024	Maturing in FY2025	Maturing in FY2026	Maturing in FY2027	Maturing in FY2028 or later
Bank debt	3 272	(522)	-	(1 975)	(775)
Lease liabilities	1 149	(505)	(133)	(89)	(422)
<b>Total debt</b>	<b>4 421</b>	<b>(1 027)</b>	<b>(133)</b>	<b>(2 064)</b>	<b>(1 197)</b>

- Currently none of the Group debt is hedged:
  - the swap curve is expensive relative to banks' expected rate cuts over the next two years; and
  - will reconsider when pricing improves.

*Making life better*

# FY 2024 | CASH FLOW FROM CONTINUING OPERATIONS

	2024 R'm	2023 R'm	% change
<b>Cash generated from operations</b>	<b>4 330</b>	3 653	18.5%
Transaction costs paid	(11)	(12)	
Net interest and tax paid	(871)	(1 139)	
Maintenance capex	(1 168)	(1 157)	
Minority distributions	(151)	(198)	
Employee share schemes	(285)	(121)	
<b>Free cash flow</b>	<b>1 844</b>	1 026	79.7
Growth capex	(385)	(366)	
Investments <sup>1</sup> and contingent consideration paid	(521)	(209)	
<b>Net cash flow after capex and investments</b>	<b>938</b>	451	108.0
Disposal of AMG, net of costs*	18 788	-	
Net repayment of interest-bearing borrowings	(8 913)	(241)	
Ordinary dividends paid to Company's shareholders	(668)	(616)	
Special dividends paid to Company's shareholders	(8 804)	-	
Other	(73)	(70)	
<b>Net movement in cash and cash equivalents from continuing operations</b>	<b>1 268</b>	(476)	>100%

- Good cash generated from operations
- Cash generated boosted by LMI's RM2 transaction
- Repaid all international debt with proceeds on disposal of AMG

<sup>1</sup> Includes acquisitions of R421m and loan to joint venture of R100m in FY2024

\*Cash proceeds, net of cash (R19 466m) less settlement of hedge (R121m) less transaction costs paid (R557m)

	2023 cps	2023 Rm	2024 cps	2024 Rm	Increase %
Interim	17	249	19	279	11.8
Final	27	396	<b>31</b>	<b>455</b>	14.8
Total	44	645	50	734	13.6
1 <sup>st</sup> Special	-	-	600	8 804	
2 <sup>nd</sup> Special	-	-	<b>70</b>	<b>1 027</b>	
Total	44	645	<b>720</b>	<b>10 565</b>	



- Final dividend: to be paid in December 2024
- 2<sup>nd</sup> special dividend: to be paid in January 2025

*Making life better*





## 2025 OUTLOOK



Southern Africa	Grow	<ul style="list-style-type: none"> <li>Growth plans:                     <ul style="list-style-type: none"> <li>219 beds:                             <ul style="list-style-type: none"> <li>79 beds in FY2025</li> <li>Commence build of 140 bed hospital</li> </ul> </li> </ul> </li> <li>Imaging transactions underway</li> <li>New PET-CT sites</li> </ul>
	Drive	<ul style="list-style-type: none"> <li>Occupancies to 70% through PPD growth of 1.0% - 1.5%</li> </ul>
	Optimise	<ul style="list-style-type: none"> <li>Focus on operational efficiencies</li> <li>Embed FMC renal operations</li> <li>Expand roll-out of renal dialysis integrated care programme</li> <li>Pursue further asset optimisation opportunities</li> </ul>
Life Molecular Imaging	Deliver	<ul style="list-style-type: none"> <li>NeuraCeq® commercial volume growth of c. 50%</li> </ul>

*Making life better*



# QUESTIONS

